An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
NCT01609036 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3
Last updated 2016-11-02
Summary
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years
Conditions
- Lymphoma, Follicular
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2012-11-30
- Completion
- 2012-11-30
Countries
- Greece
Study Locations
More Related Trials
-
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
NCT02569996 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma
NCT01200758 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
NCT01609023 ·Status: COMPLETED
-
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
NCT00430352 ·Status: COMPLETED ·Phase: PHASE4
-
Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma
NCT01560117 ·Status: COMPLETED ·Phase: PHASE2
-
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
NCT01523860 ·Status: COMPLETED ·Phase: PHASE2
-
Primary Rituximab and Maintenance
NCT00140582 ·Status: COMPLETED ·Phase: PHASE3
-
TREatment of degeNerative and Neoplastic Diseases With Rituximab
NCT01277172 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma
NCT01388959 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
NCT01609010 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
NCT01153971 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
NCT02406092 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
NCT00509184 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
NCT00269113 ·Status: COMPLETED ·Phase: PHASE3
-
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
NCT00896519 ·Status: UNKNOWN ·Phase: PHASE2
-
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
NCT00930514 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
NCT01724294 ·Status: TERMINATED
-
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
NCT00877214 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
NCT02472756 ·Status: COMPLETED
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 ·Status: COMPLETED
-
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NCT01718691 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
NCT00400478 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3